Tonix Pharmaceuticals is a pharmaceutical company based in New Jersey focused on repurposing drugs for neurological conditions and developing vaccines for COVID-19, smallpox and other biodefense projects. More recently, the FDA awarded one of its drug candidates, TNX -102 SL, with breakthrough therapy designation for the treatment of post-traumatic stress disorder following studies in the US military. Seth is an enormously accomplished physician, scientist and entrepreneur. In particular prior to co-founding Tonix, where he is now the current President and Chairman, he worked as an assistant professor at Columbia University on the team that discovered the CD40-Ligand (CD154) and elucidated the molecular basis of T cell helper function. This discovery alone has since led to the development of treatment candidates for numerous autoimmune diseases as well as for organ transplant rejection. In this episode, we cover the biotech revolution in vaccine development, the need for versatility in hiring, and inherent difficulty of “doing science” in the real world. You can find out more about Tonix Pharmaceuticals in the following ways: Website: https://www.tonixpharma.com/ Twitter: https://twitter.com/TONIXPharma LinkedIn: https://www.linkedin.com/company/tonix-pharmaceuticals/ Find us on: www.founders-keepers.com Instagram: @founderskeepers.pod Twitter: @founders.pod LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast Get in touch: hi@founders-keepers.com